# US 2016/0250324 A1 · Vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific t-cell responses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250324 A1
- Document ID: US20160250324A1
- Status: Published application
- Kind: A1
- Application number: 15/052,713
- Filed: 2016-02-24
- Published: 2016-09-01
- Earliest claimed: 2015-02-26
- Assignees: TheVax Genetics Vaccine Co., Ltd.
- Applicants: TheVax Genetics Vaccine Co., Ltd.
- Inventors: Chia-Mao WU; Jiun-Ming Wu; Yi-Tsui Chiu; Yin-Ching Lin; Hsien-Kai Chuang; Fu-Tan Hsieh; Kuan-Ming Chen
- Web page: https://patentgrep.com/patent/US20160250324A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 38/164: {from bacteria}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 39/12: Viral antigens
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2039/6031: {Proteins}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- C12N 2710/20033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/20071: Demonstrated in vivo effect
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.

## Claims

### Claim 1

A composition comprising:
(a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen;
(b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and
(c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.

### Claim 2 (depends on 1)

The composition of claim 1, further comprising at least one additive selected from the group consisting of mannitol, sucrose, trehalose, histindine, glycine, arginine, sorbitol, Polysorbate 80, glucose, lactose, maltose, maltodextrins, citrate, Tris and sodium phosphate.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the immunogenic protein is a fusion protein comprising:
(a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein;
(b) a protein transduction domain, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain, the protein transduction domain being selected from the group consisting of:
(i) a fusion polypeptide comprising:
(1) a T cell sensitizing signal-transducing peptide consisting of 28-53 amino acid residues in length, comprising the amino acid sequence of SEQ ID NO: 31, in which Xaa8 is I or L; Xaa10 is V, F or A, Xaa11 is M or L, Xaa17 is L or I, being located at the N-terminus of the fusion polypeptide;
(2) a translocation peptide consisting of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 20 or 4; and
(3) a linker, comprising SEQ ID NO: 15 linking the T cell sensitizing signal-transducing peptide and the translocation peptide;
(ii) a T cell-sensitizing signal-transducing peptide consisting of 28-53 amino acid residues in length, comprising the amino acid sequence of SEQ ID NO: 31, in which Xaa8 is I or L; Xaa10 is V, F or A, Xaa11 is M or L, Xaa17 is L or I; and
(iii) a translocation peptide of 34-46 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3 or 20; and
(c) an antigen of a pathogen, located at the C-terminus of the protein transduction domain; wherein the APC-binding domain or the CD91 receptor-binding domain is free of the amino acid sequence of Pseudomonas exotoxin A (PE) binding domain I if the protein transduction domain is the translocation peptide of 34-46 amino acid residues in length in (b)(iii).

### Claim 4 (depends on 3)

The composition of claim 3, wherein the protein transduction domain comprises the sequence of SEQ ID NO: 30.

### Claim 5 (depends on 3)

The composition of claim 3, wherein the APC-binding domain or the CD91 receptor-binding domain is a polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence selected from the group consisting of SEQ ID NOs: 5, 9, 6, 7, and 8.

### Claim 6 (depends on 3)

The composition of claim 3, wherein the T cell sensitizing signal-transducing peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 and 2.

### Claim 7 (depends on 3)

The composition of claim 3, wherein the translocation peptide comprises the amino acid sequence of SEQ ID NO: 3.

### Claim 8 (depends on 3)

The composition of claim 3, wherein the pathogen is at least one selected from the group consisting of Human Papillomavirus (HPV), Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), Human Immuno-deficient Virus (HIV-1), flu virus, dengue virus, Hepatitis C virus (HCV), Hepatitis B virus (HBV) and Porcine Circovirus 2 (PCV2).

### Claim 9 (depends on 3)

The composition of claim 3, wherein the antigen of a pathogen is selected from the group consisting of Human Papillomavirus (HPV) E7 protein, Hepatitis B virus (HBV) HBx protein, Hepatitis C virus (HCV) core antigen, Flu virus M2 antigen, and a tumor associated antigen.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the tumor associated antigen is selected from the group consisting of SSX2, MAGE-A3, NY-ESO-1, iLRP, WT12-281, RNF43 (2-116+696-783), and CEA-NE3.

### Claim 11 (depends on 9)

The composition of claim 9, wherein the HPV E7 protein comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 21.

### Claim 12 (depends on 3)

The composition of claim 3, wherein the fusion protein further comprises an endoplasmic reticulum retention sequence located at the C-terminus of the fusion protein.

### Claim 13 (depends on 3)

The composition of claim 3, wherein the fusion protein is free of an endoplasmic reticulum retention sequence at the C-terminus of the fusion protein provided that the antigen contains 10 or more epitopes.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the immunogenic protein is a fusion protein comprising:
(a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein;
(b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 4, 20, or 41, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and
(c) an antigen of a pathogen;
(d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 44; and
(e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein;
wherein the nuclear export signal is located between the antigen and the endoplasmic reticulum retention sequence, or between the translocation peptide and the antigen.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the C-terminal amino acid of the SEQ ID NO: 44 is alanine.

### Claim 16 (depends on 14)

The composition of claim 14, wherein the nuclear export signal comprises the amino acid sequence of SEQ ID NO: 45.

### Claim 17 (depends on 14)

The composition of claim 14, wherein the pathogen is selected from the group consisting of Porcine reproductive and respiratory syndrome virus (PRRSV), Porcine Circovirus 2 (PCV2), Foot-and-mouth disease virus (FMDV), Classical Swine Fever Virus (CSFV), Newcastle disease virus (NDV), Transmissible gastroenteritis virus (TGEV), Porcine epidemic diarrhea virus (PEDV), Influenza virus, Pseudorabies virus, Parvovirus, Pseudorabies virus, Swine vesicular disease virus (SVDV), Poxvirus, Rotavirus, Mycoplasma pneumonia, Herpes virus, Infectious bronchitis, and Infectious bursal disease virus.

### Claim 18 (depends on 14)

The composition of claim 14, wherein the APC-binding domain or the CD91 receptor-binding domain comprises the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 9.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the immunogenic protein is a fusion protein comprising:
(a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein;
(b) a translocation peptide of 34-61 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 20, or 41, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and
(c) an antigen of a pathogen;
(d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 44; and
(e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein;
wherein the nuclear export signal is located between the antigen and the endoplasmic reticulum retention sequence, or between the translocation peptide and the antigen.

### Claim 20 (depends on 1)

A method for inducing enhanced pathogen antigen-specific T cell responses, comprising: administering the composition of claim 1 to a subject in need thereof, and thereby inducing the enhanced pathogen antigen-specific T cell responses.
